Most Sales in the Parkinson's Disease Drug Market Will Continue to Be Driven by the Leading Dopamine Agonists Pramipexole and Ropinirole Coupled with the Reentry of UCB's Neupro/Leganto to the U.S. Market
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the leading dopamine agonists, pramipexole (Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol/BI-Sifrol, generics; Mirapex ER/Mirapexin ER/Sifrol Retard/Mirapex LA) and ropinirole (GlaxoSmithKline's Requip, generics; GlaxoSmithKline/SkyePharma's Requip XL/LP/RP/Modutab/Prolib, generics), will continue to garner the most substantial sales among therapies used to treat Parkinson's disease. Additionally, the recent reentry of UCB's Neupro/Leganto to the U.S. market, its expanding use in Europe and its forecasted launch in Japan will likewise make it one of the top-selling Parkinson's disease therapies, owing to its once-daily dosing, convenient transdermal delivery, and premium pricing.
The Pharmacor advisory service entitled Parkinson's Disease also finds that overall sales of therapies to treat the disease will remain relatively flat over the next decade, rising from $2.4 billion in 2011 to $2.5 billion in 2021 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Sustaining sales will be the increased uptake of key current Parkinson's disease therapies and the launch of three new therapies, but growth will be offset by ever-increasing generic competition.
Impax Laboratories/GlaxoSmithKline's Rytary, a reformulation of levodopa (multiple brands, generics), will contribute moderately to market growth. Rytary's expected use, at least initially, will be primarily for more-advanced disease stages, driven by its effect on reducing “off” time (periods of motor disability that become more pronounced as Parkinson's disease progresses) and its dosing frequency, which is expected to be more advantageous in later rather than earlier disease stages. Also contributing positively to market sales will be the emerging MAO-B inhibitor safinamide (Newron Pharmaceuticals/Zambon Pharma/Meiji Seika Pharma), which will benefit from use both in early Parkinson's disease for control of mild motor symptoms and in advanced Parkinson's disease for the management of levodopa-induced motor response complications (MRCs). As a first-in-class agent, Kyowa Hakko Kirin's adenosine A2A receptor antagonist istradefylline will also benefit from use in the management of MRCs, but its market impact will be comparatively minor because Decision Resources currently expects it to launch only in Japan.
Conversely, market growth will be constrained through 2021 by the increased uptake of generic versions of ropinirole (both immediate- and controlled-release formulations) and pramipexole (both immediate- and extended-release formulations), as well as the entrance of generic versions of other prominent Parkinson's disease agents, entacapone (Novartis/Orion Pharma's Comtan/Comtess/Stalevo, generics) and Teva/Lundbeck's Azilect/Agilect.
“By 2021, the genericization of several key Parkinson's disease therapies will have created a fragmented market with no clear leader, as a large number of similarly priced drugs compete for the same patient share,” said Decision Resources Analyst Nadja Rozovsky, Ph.D. “Future therapies will need to clearly differentiate themselves from other therapies to gain a competitive edge in this mature market.”
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
Christopher Comfort, 781-993-2597